Exosome Isolation


Look to BioFluidica LiquidScan for Extracellular Vesicle (EVs) exosome isolation. BioFluidica created LiquidScan to affinity capture and thereby enrich the concentration of biomarkers in liquid biopsy samples. These biomarkers include rare cells like circulating tumor cells (CTCs) and fetal cells (trophoblasts) and, importantly, Extracellular Vesicles (EVs; exosomes). EVs (exosomes) are ideally suited to be developed for liquid biopsy diagnostic analysis for early diagnosis, molecular profiling, disease surveillance, and treatment response monitoring. Numerous studies describe the functional significance of exosomes in a wide variety of cancers, for example. To move research studies into the clinic, however, requires a reproducible accurate, and automated methodology and one that can isolate specific exosome subtypes.

*LiquidScan is the unique solution to isolate exosome subtypes for biomarker research and diagnostics development. BioFluidica exosome experts have experience capturing EVs with antibodies against pan-EV markers (CD9, CD63, CD81) and cancer-specific markers (EPCAM, FAPalpha, CD24, PD-L1).


With many treatment options available for diverse types of cancers, regular follow-up and treatment maintenance have become critical for patient success. While tissue biopsy remains standard practice for cancer diagnosis and initial treatment decisions, researchers have found promise in minimally invasive liquid biopsies for ongoing treatment decisions. Liquid biopsy samples include blood, urine, saliva, and other bodily fluids and contain cell-free DNA (cfDNA – circulating tumor DNA; ctDNA), Circulating Tumor Cells (CTCs), and Extracellular Vesicles (EVs), a subset of which is a milieu of exosomes. Exosomes are small, lipid-bilayer bound Extracellular Vesicles (EVs) of 40–160 nanometers in size that carry important information for intercellular communication. Exosomes are produced more by tumor cells than normal cells and carry tumor-specific content, such as DNA, RNA, and proteins, which have been implicated in tumorigenesis, tumor progression, and treatment response. Due to the critical role of exosomes in cancer development and progression, they can be exploited to develop specific biomarkers and therapeutic targets.


The rising demand for fast, accurate, and minimally invasive diagnostic procedures represents a promising opportunity for the growth of liquid biopsy applications. In particular, the relative robustness of EVs during isolation from plasma provides a valuable entity which is experiencing more interest as a basis for developing diagnostic tests.

  • BioFluidica surfaces the channels of the LiquidScan microfluidic chip with antibodies directed against your EVs of interest.
  • Any EV with specific cell surface markers can be isolated using *LiquidScan.
  • BioFluidica *LiquidScan uniquely enriches liquid biopsy samples for EVs.
  • EVs isolated by *LiquidScan are ready for downstream molecular interrogation.
  • *LiquidScan captures specific EVs with high purity, integrity, and reproducibility dependent on the liquid biopsy sample.
  • Multiple antibodies can be used per single chip, or different antibody chips can be used in series.

Schedule a consultation with our research team to discuss your specific needs.

*LiquidScan is for Research Use Only


BioFluidica is a privately held biotechnology and liquid biopsy company. We have developed a revolutionary liquid biopsy platform allowing for the isolation and analysis of all liquid biopsy biomarkers, including rare cells, extracellular vesicles (EVs; exosomes), and cfDNA, on one fully automated platform. The Biofluidica platform has been clinically tested on nine different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. The ultralow sensitivity expands the capability of current liquid biopsy applications. We are expert consultants in exosome isolation, fetal cell (trophoblast)  isolation, CTC isolation, and next-generation liquid biopsy. We develop and launch innovative scientific instruments, reagents, and software systems designed to provide exceptional value for scientists, clinicians, and patients.